HIV drug coverage in sub-Saharan Africa continues to improve but not sustainable, UNAIDS' Sidibe says

At the end of 2011, 6.2 million people in sub-Saharan Africa were taking antiretroviral drugs, about 56 percent of the people in need in the region, UNAIDS Executive Director Michel Sidibe noted in an interview last week, saying, "Ten years ago, nobody would have imagined that such a result would be possible," Agence France-Presse reports. "Sidibe -- visiting Paris ahead of the July 22-27 International AIDS Conference in Washington -- said he was worried that African countries remained so dependent on foreign help," the news service states. "With the exception of South Africa, 80 percent of Africans with HIV have access to drugs via funding from outside Africa. This is not sustainable. It's even dangerous," he said, according to the news service.

Sidibe "added he would call for an African Medicines Regulatory Agency at an Africa Union summit, taking place in Addis Ababa from July 13 to 15," AFP notes, adding, "The proposed agency would vet drugs, given the widening problem of fake or below-quality medications that are being sold in Africa, and encourage local production of" antiretroviral drugs (7/6). "Africa's dependency on external aid is destabilizing the HIV response. ... Leaders across the African continent are poised to transcend the outdated donor-recipient paradigm and embrace a new compact for shared responsibility and global solidarity," Sidibe said in a UNAIDS press release (7/6).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers key mechanism behind HIV latency